Publications by authors named "Zijia Dou"
Hyperlipidemia is a major risk factor for hypertension, coronary heart disease, diabetes and stroke, triggering an intensified research efforts into its prevention and treatment. Tetrahydroberberrubine (THBru) is a derivative of berberine (BBR) that has been shown to have higher bioavailability and lower toxicity compared to its parent compound. However, its impact on hyperlipidemia has not been fully explored.
View Article and Find Full Text PDFBerberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis.
Biomed Pharmacother
August 2024
Article Synopsis
- A new study discovered that berberine (BBR) can inhibit the protein ACSL4, which is linked to cell damage through ferroptosis, and this could help protect against atherosclerosis.
- Researchers created a mouse model with a high-fat diet to simulate atherosclerosis and tested the effects of BBR on both this model and human endothelial cells damaged by oxidized low-density lipoprotein (ox-LDL).
- Findings showed that BBR not only inhibits ferroptosis associated with ACSL4 but also reduces lipid buildup and plaque formation, suggesting it could be a promising treatment strategy for atherosclerosis.
THBru attenuates diabetic cardiomyopathy by inhibiting RAGE-dependent inflammation.
Acta Pharmacol Sin
October 2024
Diabetic cardiomyopathy (DCM) is a complication of diabetes mellitus characterized by heart failure and cardiac remodeling. Previous studies show that tetrahydroberberrubine (THBru) retrogrades cardiac aging by promoting PHB2-mediated mitochondrial autophagy and prevents peritoneal adhesion by suppressing inflammation. In this study we investigated whether THBru exerted protective effect against DCM in db/db mice and potential mechanisms.
View Article and Find Full Text PDF